Wechselwirkungen · Simulect
Simulect 20 mg powder and solvent for solution for injection or infusion Simulect 20 mg powder for solution for injection or infusion · Abschnitt 4.5 · PDF-Seite 5
HOS-089006 · Präparat HOS-083755
Three clinical trials have investigated basiliximab use in combination with a triple therapy regimen which included either azathioprine or mycophenolate mofetil. The total body clearance of basiliximab was reduced by an average 22% when azathioprine was added to a regimen consisting of ciclosporin for microemulsion and corticosteroids. The total body clearance of basiliximab was reduced by an average 51% when mycophenolate mofetil was added to a regimen consisting of ciclosporin for microemulsion and corticosteroids. The use of basiliximab in a triple therapy regimen including azathioprine or mycophenolate mofetil did not increase adverse events or infections in the basiliximab group as compared to placebo (see section 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azathioprine (HOS-089001) mycophenolate mofetil (HOS-085154) placebo (HOS-088378)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-19T11:51:00Z · SHA-256 733fba3a740348b21107babe9d9387936dfd68357cde53822fb186eb4a9d7e0d · Passage d9ac0d08b763395ed52ccfd6a3db09312ae59258cd52ba42239ca8173921e687 · Zeichen 1443–2177 im Abschnitt